• Single-Molecule Screening of Fast-Dissociating Anti-FLAG Ant

  2026-05-19

  Miyoshi et al. introduce a semi-automated single-molecule microscopy screen for fast-dissociating, highly specific monoclonal antibodies directly from hybridoma cultures. This approach enables the identification of antibodies ideal for advanced super-resolution imaging and highlights the not-uncommon existence of fast-dissociating, specific anti-epitope tag antibodies, such as those against the FLAG tag Peptide.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Stability, Innovati

  2026-05-18

  Explore the unique stability and translational efficiency of Firefly Luciferase mRNA (ARCA, 5-moUTP) in advanced gene expression and imaging assays. This in-depth article reveals new scientific insights, practical protocol guidance, and the latest evidence from nanoparticle delivery research.

• BMSC Exosomal Egr2 Modulates RNF8/DAPK1 Axis in Ischemic Str

  2026-05-18

  The cited study uncovers how bone marrow-derived mesenchymal stem cell (BMSC) exosomes enriched in Egr2 protect neurons from oxygen-glucose deprivation/reoxygenation (OGD/R) injury via the RNF8/DAPK1 pathway. This mechanistic insight refines our understanding of stem cell-based neuroprotection and highlights molecular targets for future stroke therapeutics.

• Triptolide (PG490): Precision Transcriptional Inhibition in

  2026-05-17

  Explore how Triptolide (PG490) enables precision inhibition of genome activation and transcription in both cancer and pluripotency models. This article uniquely connects developmental reprogramming with translational oncology, offering advanced assay guidance for researchers.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-05-16

  This study presents a combinatorial library of ROS-degradable lipid nanoparticles that preferentially deliver mRNA into tumor cells, exploiting elevated intracellular ROS to achieve controlled, selective gene expression. The approach demonstrates superior tumor targeting and functional delivery compared to conventional methods, with strong translational implications for targeted mRNA therapeutics.

• O-propargyl-puromycin: Precision Protein Synthesis Assays

  2026-05-15

  O-propargyl-puromycin (OPP) unlocks high-resolution, quantitative mapping of nascent protein synthesis in living cells. This article offers advanced experimental workflows, protocol optimization, and troubleshooting strategies to maximize OPP's impact in immunology and proteomics research.

• Berberine Hydrochloride: Applied Workflows in Metabolic Dise

  2026-05-15

  Berberine hydrochloride empowers metabolic and inflammation research through validated AMPK activation and precise LDL receptor upregulation. This article delivers optimized protocols, troubleshooting strategies, and data-driven insights to maximize reproducibility and experimental success with APExBIO’s trusted reagent.

• Tofacitinib Reverses Inflammation and Mitochondrial Dysfunct

  2026-05-14

  This study demonstrates that tofacitinib (CP-690550) uniquely reverses both inflammatory and metabolic dysregulation in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. By inhibiting STAT5 signaling and restoring mitochondrial function, tofacitinib offers mechanistic insight and a compelling research tool for dissecting cytokine-driven macrophage pathology.

• Go 6983 (pan-PKC Inhibitor): Transforming PKC Pathway Resear

  2026-05-14

  Go 6983 (pan-PKC inhibitor) empowers researchers to dissect complex PKC-dependent signaling in cancer, EMT, and embryogenesis with nanomolar precision. This guide delivers actionable workflows, troubleshooting insights, and protocol enhancements bridging breakthrough mechanistic findings to the bench.

• Translational Leverage of ddhCTP in RNA Virus Inhibition

  2026-05-13

  An expert synthesis for translational researchers: uncovering the mechanistic underpinnings of ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) as a targeted RNA virus replication inhibitor, with strategic guidance on experimental design, translational application, and future antiviral drug development.

• 2-Hydroxypropyl-β-cyclodextrin: Solubility Optimization Guid

  2026-05-13

  2-Hydroxypropyl-β-cyclodextrin addresses the challenge of formulating poorly water-soluble, hydrophobic research compounds—especially those with aromatic or phenyl groups—by forming inclusion complexes to enhance aqueous solubility. It should be used as a solubilization excipient in pharmaceutical or biochemical workflows; applications outside solubility enhancement are not supported by current product documentation.

• HyperScribe™ T7 Cy3 RNA Labeling Kit: Probing lncRNA Biology

  2026-05-12

  Explore how the HyperScribe T7 High Yield Cy3 RNA Labeling Kit enables high-resolution, fluorescent RNA probe generation for advanced lncRNA research in sepsis. Discover unique applications, protocol insights, and key scientific findings that differentiate this kit for in situ hybridization and biomarker discovery.

• FPH1 (BRD-6125): Optimizing Hepatocyte Proliferation Assays

  2026-05-12

  FPH1 (BRD-6125) enables robust, donor-independent expansion of primary human hepatocytes, supporting advanced workflows in drug metabolism and regenerative medicine. This guide distills evidence-based protocols, troubleshooting strategies, and experimental innovations to maximize functional hepatocyte yields in vitro.

• Eliminating Pollen Interference in Bioaerosol Fluorescence D

  2026-05-11

  The referenced study introduces a robust spectral transformation and machine learning approach to remove pollen interference in excitation–emission matrix (EEM) fluorescence spectroscopy for hazardous bioaerosol classification. These advances significantly improve the accuracy and reliability of rapid detection workflows for bacterial pathogens and toxins in complex environmental samples.

• PARP7 Inhibition Restores STAT1/2 and Alleviates EAE in Mice

  2026-05-11

  Xu et al. reveal how PARP7-mediated ADP-ribosylation targets STAT1/2 for autophagic degradation, suppressing type I interferon signaling in autoimmune encephalomyelitis. Pharmacological inhibition of PARP7 stabilizes STAT1/2, restores interferon activity, and reduces disease severity in a mouse model, offering mechanistic insight and translational promise for multiple sclerosis research.

405 records 8/27 page Previous Next First page 上5页 678910 下5页 Last page